Literature DB >> 22359046

Effective production of anti-tetanus toxoid and anti-HBsAg human monoclonal antibodies by serum-free culture of hybridomas.

K Kitano1, Y Ichimori, H Sawada, S Iwasa, S Sasai, K Tsukamoto.   

Abstract

Two hybridoma systems, mouse·human-human (m·h-h) heterohybridoma and human-human (h-h) hybridoma, have been established, and hybridomas secreting anti-tetanus toxoid and anti-HBsAg human monoclonal antibodies (MoAbs), both having a neutralizing activity have been obtained. Cell-line improvement was shown to be an efficient method for improving the productivity in a cell culture process. Two kinds of serum-free media, GFS (a serum substitute)-containing media and polyethylene glycol (PEG)-containing media, have been established to produce human MoAbs. m·h-h Heterohybridomas could be cultivated for a long period by perfusion culture in an agitation vessel, but h-h hybridomas could not. We found that h-h hybridomas show growth-associated antibody production kinetics and established two kinds of long-term cultivation systems: continuous perfusion culture and semicontinuous immobilized perfusion culture. We also scaled up batch culture and short-term perfusion culture to 200-L and 50-L fermentors, respectively. Processes for large-scale purification from the culture supernatants of both GFS- and PEG-containing serum-free media have also been developed.

Entities:  

Year:  1991        PMID: 22359046     DOI: 10.1007/BF00573880

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  53 in total

1.  Identification of the target cells in human B lymphocytes for transformation by Epstein-Barr virus.

Authors:  T Katsuki; Y Hinuma; N Yamamoto; T Abo; K Kumagai
Journal:  Virology       Date:  1977-12       Impact factor: 3.616

2.  Spin filter culture: the propagation of mammalian cells in suspension.

Authors:  P Himmelfarb; P S Thayer; H E Martin
Journal:  Science       Date:  1969-05-02       Impact factor: 47.728

3.  Requirements for the establishment of high-titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique.

Authors:  D Kozbor; J C Roder
Journal:  J Immunol       Date:  1981-10       Impact factor: 5.422

4.  Effective production of a human monoclonal antibody against tetanus toxoid by selection of high productivity clones of a heterohybridoma.

Authors:  K Kitano; K Iwamoto; Y Shintani; S Akiyama
Journal:  J Immunol Methods       Date:  1988-04-22       Impact factor: 2.303

5.  A human monoclonal IgG1 lambda anti-hepatitis B surface antibody. Production, properties, and applications.

Authors:  E A Stricker; R F Tiebout; P N Lelie; W P Zeijlemaker
Journal:  Scand J Immunol       Date:  1985-09       Impact factor: 3.487

6.  Growth of T-lymphoma cells in serum-free medium: lack of involvement of the cyclic AMP pathway in long-term cultures.

Authors:  F J Darfler; H Murakami; P A Insel
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

7.  Protective human hybridoma antibody to tetanus toxin.

Authors:  F Gigliotti; R A Insel
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

8.  Production of human hybridomas secreting antibodies to measles virus.

Authors:  C M Croce; A Linnenbach; W Hall; Z Steplewski; H Koprowski
Journal:  Nature       Date:  1980-12-04       Impact factor: 49.962

9.  Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity.

Authors:  L Olsson; H S Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

10.  Human monoclonal antibody against Forssman antigen.

Authors:  R Nowinski; C Berglund; J Lane; M Lostrom; I Bernstein; W Young; S I Hakomori; L Hill; M Cooney
Journal:  Science       Date:  1980-10-31       Impact factor: 47.728

View more
  1 in total

Review 1.  Perfusion culture apparatus for suspended mammalian cells.

Authors:  M Tokashiki; H Takamatsu
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.